Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

135 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-30

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal is to examine the efficacy and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Uzbekistan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Ukraine

NCT02415894

Other Abortion

COMPLETED

Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia

NCT01766388

Abortion in Second Trimester

COMPLETED

Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso

NCT03269279

Medical; Abortion, Fetus

UNKNOWN PHASE3

Mifepristone and Mid-Trimester Termination of Pregnancy

NCT00382538

Abortion, Induced Abortion, Second Trimester

COMPLETED NA

Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan

NCT02018796

Complete Abortion

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abortion in Second Trimester

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women of 13-22 weeks gestation

Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet legal criteria to obtain abortion
* Have an ongoing pregnancy of 13-22 weeks gestation
* Be willing to undergo a surgical completion if necessary
* Have no contraindications to study procedures, according to provider
* Be willing and able to consent to procedure, either by reading consent document or by having consent document read to her
* Be willing to follow study procedures

Exclusion Criteria

* Known previous transmural uterine incision
* Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
* Any contraindications to vaginal delivery, including placenta previa

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes